CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase

BE0014269ProteinHumansST3GAL3

Catalyzes the formation of the NeuAc-alpha-2,3-Gal-beta-1,4-GlcNAc-, NeuAc-alpha-2,3-Gal-beta-1,3-GlcNAc- and NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc- sequences found in terminal carbohydrate groups of glycoproteins and glycolipids. It is acted on by 1 drug in DrugBank.

Gene name
ST3GAL3
UniProtKB entry
Q11203Swiss-Prot
Cellular location
Golgi apparatus, Golgi stack membrane
Residues / weight
375 residues · 42,170 Da
Also known as
2.4.3.6 · Alpha 2,3-ST 3 · Beta-galactoside alpha-2,3-sialyltransferase 3 · Gal beta-1,3(4) GlcNAc alpha-2,3 sialyltransferase · N-acetyllactosaminide alpha-2,3-sialyltransferase

Resolves to

Protein
UniProtQ11203UniProt nameSIAT6_HUMAN
Gene
HGNCHGNC:10866NCBI Gene6487GeneCardsST3GAL3
Pharmacology
KEGGhsa:6487
Drugs

What you can answer from here — as of September 03, 2024

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
13GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which compounds in development act on CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In